108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于溃疡性结肠炎的发病机制：中医治疗溃疡性结肠炎综述
Authors Huang Y, Ma Z, Xu X, Liu Z
Received 5 April 2025
Accepted for publication 8 July 2025
Published 25 September 2025 Volume 2025:18 Pages 5811—5829
DOI https://doi.org/10.2147/IJGM.S532534
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Xudong Zhu
Yan Huang,1 Zhuolin Ma,2 Xiaonan Xu,1 Zhaoxia Liu1
1First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150000, People’s Republic of China; 2Heilongjiang Eye Hospital, Harbin, Heilongjiang, 150007, People’s Republic of China
Correspondence: Xiaonan Xu, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin City, Heilongjiang, 150000, People’s Republic of China, Email 1509726765@qq.com Zhaoxia Liu, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin City, Heilongjiang, 150006, People’s Republic of China, Email hlj0451lzx@163.com
Abstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum that has become an increasing global health concern. Its pathogenesis is multifactorial, involving genetic susceptibility, environmental triggers, epithelial barrier dysfunction, gut microbiota imbalance, and immune dysregulation. Clinically, UC is characterized by bloody diarrhea, mucosal inflammation, and a relapsing-remitting course, with diagnosis typically confirmed by clinical, endoscopic, histological, and laboratory findings. Despite the increasing number of therapeutic options, including corticosteroids, immunosuppressants, and biologics, many patients still experience suboptimal responses or adverse events, and some ultimately require colectomy. In this context, Traditional Chinese Medicine (TCM) has attracted attention as a complementary approach due to its multi-target mechanisms and historical use in gastrointestinal diseases. This review summarizes recent evidence on the application of TCM in UC, including its theoretical foundations, active compounds, and modulation of key signaling pathways such as TLR4/NF-κB, NLRP3, JAK/STAT3, PI3K/Akt, Notch, and AMPK/mTOR. Additionally, we highlight clinical data from randomized controlled trials (RCTs) evaluating TCM formulas either as monotherapy or in combination with conventional treatments. Some studies report improvements in symptom scores, inflammatory markers, and endoscopic healing when TCM is combined with agents like mesalazine. However, these findings must be interpreted with caution. Most RCTs are single-center with small sample sizes, lack placebo control, and show considerable heterogeneity in intervention protocols and outcome assessments, making quantitative comparisons to standard therapies, such as remission rates or adverse event frequencies relative to mesalazine or biologics, being limited. Therefore, while TCM demonstrates therapeutic potential in UC management, more rigorous evidence is needed to establish its comparative efficacy and safety. Future studies should include large-scale, multicenter, placebo-controlled RCTs with standardized endpoints, and consider integrating TCM syndrome differentiation with modern pathophysiological frameworks to enhance clinical relevance and translational value.
Keywords: ulcerative colitis, diarrhea, hematochezia, defecation difficulty, mucosal barrier, traditional Chinese medicine
1First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150000, People’s Republic of China; 2Heilongjiang Eye Hospital, Harbin, Heilongjiang, 150007, People’s Republic of China
Correspondence: Xiaonan Xu, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin City, Heilongjiang, 150000, People’s Republic of China, Email 1509726765@qq.com Zhaoxia Liu, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Xiangfang District, Harbin City, Heilongjiang, 150006, People’s Republic of China, Email hlj0451lzx@163.com
Abstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon and rectum that has become an increasing global health concern. Its pathogenesis is multifactorial, involving genetic susceptibility, environmental triggers, epithelial barrier dysfunction, gut microbiota imbalance, and immune dysregulation. Clinically, UC is characterized by bloody diarrhea, mucosal inflammation, and a relapsing-remitting course, with diagnosis typically confirmed by clinical, endoscopic, histological, and laboratory findings. Despite the increasing number of therapeutic options, including corticosteroids, immunosuppressants, and biologics, many patients still experience suboptimal responses or adverse events, and some ultimately require colectomy. In this context, Traditional Chinese Medicine (TCM) has attracted attention as a complementary approach due to its multi-target mechanisms and historical use in gastrointestinal diseases. This review summarizes recent evidence on the application of TCM in UC, including its theoretical foundations, active compounds, and modulation of key signaling pathways such as TLR4/NF-κB, NLRP3, JAK/STAT3, PI3K/Akt, Notch, and AMPK/mTOR. Additionally, we highlight clinical data from randomized controlled trials (RCTs) evaluating TCM formulas either as monotherapy or in combination with conventional treatments. Some studies report improvements in symptom scores, inflammatory markers, and endoscopic healing when TCM is combined with agents like mesalazine. However, these findings must be interpreted with caution. Most RCTs are single-center with small sample sizes, lack placebo control, and show considerable heterogeneity in intervention protocols and outcome assessments, making quantitative comparisons to standard therapies, such as remission rates or adverse event frequencies relative to mesalazine or biologics, being limited. Therefore, while TCM demonstrates therapeutic potential in UC management, more rigorous evidence is needed to establish its comparative efficacy and safety. Future studies should include large-scale, multicenter, placebo-controlled RCTs with standardized endpoints, and consider integrating TCM syndrome differentiation with modern pathophysiological frameworks to enhance clinical relevance and translational value.
Keywords: ulcerative colitis, diarrhea, hematochezia, defecation difficulty, mucosal barrier, traditional Chinese medicine